1. Introduction {#sec1}
===============

Traumatic brain injury (TBI) is known to cause several secondary effects, which lead to peripheral organs dysfunction. The close relationship between brain injury and subsequent intestinal mucosal injury has been recognized \[[@B1], [@B2]\]. This pathologic course may not only influence the intestinal mucosa itself but also impair the remote organs, leading to systemic inflammatory response syndrome (SIRS) and multiple-organ dysfunction syndrome (MODS) \[[@B3]\]. Previous studies of our laboratory demonstrated that traumatic brain injury could lead to intestinal inflammatory response mediated by increased nuclear factor kappa B (NF-*κ*B) and proinflammatory cytokines, which played a critical role in the pathogenesis of acute gut mucosal injury following TBI \[[@B4], [@B5]\]. Afterwards, using nuclear factor erythroid 2-related factor 2 (Nrf2) knockout mice, we found that Nrf2, which is the key transcription factor that mediates the induction of cellular antioxidant defense mechanisms, played an important protective role in limiting TBI-induced intestinal inflammatory response and gut mucosal injury \[[@B6], [@B7]\]. However, it is not known whether activation of the factor Nrf2 has a protective effect in the intestinal inflammation associated with TBI.

A wide range of natural and synthetic small molecules with diverse chemical backgrounds have been shown to induce the Nrf2 activity; tert-butylhydroquione (tBHQ) is the major one that exerts powerful antioxidant potential \[[@B8]--[@B10]\]. It has been documented that tBHQ protects the animals and cell lines against acute toxicity and oxidative insult, presumably through the induction of many cytoprotective and detoxifying enzymes such as epoxide hydrolase \[[@B11]\], glutathione-S-transferase \[[@B12]\], and glucoronyltransferase \[[@B13]\]. This activation is dependent on the translocation of Nrf2 from the cytoplasm to the nucleus through inducer interaction with Keap1, the cytoplasmic repressor of Nrf2 \[[@B14]\]. Nevertheless till now, no study was found in the literature to address the therapeutic effect of the activation of Nrf2 by tBHQ on the TBI-induced intestinal inflammatory response. The purpose of the current study was therefore to determine the influence of tBHQ administration on intestinal NF-*κ*B activity, proinflammatory cytokines expression, and apoptosis after TBI.

2. Materials and Methods {#sec2}
========================

2.1. Animals {#sec2.1}
------------

All procedures were approved by the Institutional Animal Care Committee and were in accordance with the guidelines of the National Institutes of Health on the care and use of animals. Age- and weight-matched adult male ICR mice (6--8 weeks, 28--32 g) were purchased from Animal Center of Chinese Academy of Sciences, Shanghai, China. Mice were housed at 23 ± 1°C in humidity-controlled animal quarters with 12-hour light/dark cycle.

2.2. Experimental Protocol {#sec2.2}
--------------------------

The experimental groups consisted of sham + vehicle group, TBI + vehicle group, and TBI + tBHQ group (*n* = 12 per group). Mice of TBI + tBHQ group were fed the tBHQ-supplemented diet for one week prior to injury, but mice of sham + vehicle group and TBI + vehicle group were given the control food. For tBHQ feeding, food pellets were powdered in a coffee grinder and dry mixed with 1% tBHQ (w/w). Distilled water was added to the powder (equal v/w), thoroughly mixed, and reshaped into food pellets. The pellets were then baked at 60°C for 3 h. Control food was processed in the same manner without the addition of tBHQ \[[@B15]\]. This dose and medication of tBHQ administration have been widely used in analogous animal models described elsewhere \[[@B15], [@B16]\].

The mouse model of TBI was employed as described \[[@B17]\] being previously developed in our laboratory \[[@B18]\]. Mice were anesthetized by intraperitoneal injection with sodium pentobarbital (50 mg/kg). A round, flat, and 6 mm diameter Teflon impounder was centered between the ears and eyes. TBI was induced by a 100 g weight dropped from a 12 cm height along a stainless steel string, which translated into 1200 g/cm. This model is generally associated with 20% mortality within the first 5 min after injury, and no delayer mortality was observed thereafter \[[@B18]\]. Sham mice were subjected to identical treatment with the exception that no injury was performed.

Animals were decapitated at 24 h following sham or injury for sample collection. Six mice in each group were sacrificed for electrophoretic mobility shift assay (EMSA) and enzyme-linked immunosorbent assay (ELISA), the others were for immunohistochemistry and terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) study. For EMSA and ELISA analysis, mice were exsanguinated by cardiac puncture, and a 3-cm segment of the jejunum 8 cm distal to Treitz ligament was rapidly removed and stored at liquid nitrogen immediately. For immunohistochemistry and TUNEL study, mice were perfused via left ventricular puncture with cold saline (4°C), followed by 4% neutral buffered formalin. The 3-cm segment of the jejunum was taken, stored overnight in 4% neutral buffered formalin, and then embedded in paraffin.

2.3. Nuclear Protein Extract and EMSA {#sec2.3}
-------------------------------------

The DNA binding activity of NF-*κ*B in intestine was determined by EMSA. Nuclear protein of intestinal tissue was extracted and quantified as described previously in \[[@B6]\]. EMSA was performed using a commercial kit (Gel Shift Assay System; Promega, Madison, WI) following the methods in our laboratory. A Consensus oligonucleotide probe for NF-*κ*B (5′-AGT TGA GGG GAC TTT CCC AGG C-3′) was end-labeled with \[*γ*-^32^P\]-ATP (Free Biotech., Beijing, China) with T4-polynucleotide kinase. EMSA was performed according to our previous study \[[@B6]\]. NF-*κ*B activity was quantified by computer-assisted densitometric analysis.

2.4. ELISA Analysis {#sec2.4}
-------------------

The intestinal levels of inflammatory cytokines such as tumor necrosis factor-*α* (TNF-*α*), interleukin-1*β* (IL-1*β*), and interleukin-6 (IL-6) were quantified using ELISA kits specific for mouse according to the manufacturers\' instructions (TNF-*α* from Diaclone Research, France; IL-1*β*, IL-6 from Biosource Europe SA, Belgium) and our previous study \[[@B6]\]. The cytokine contents in the intestinal tissue were expressed as pg per milligram protein.

2.5. Immunohistochemical Staining {#sec2.5}
---------------------------------

The paraffin-embedded sections (4 *μ*m) were used for Immunohistochemical assay, which was performed with a goat antimouse intercellular adhesion molecule-1 (ICAM-1) antibody (diluted 1 : 200, R&D Systems, Inc., Minnesota, USA), according to our previous study \[[@B6]\]. Microscopy of the immunohistochemically stained tissue sections was performed by an experienced pathologist blinded to the experimental condition. Evaluation of sections was undertaken by assessing the intensity of staining (5 grades). "0" indicates no detectable positive cell; "1" indicates very low density of positive cells, "2" indicates a moderate density of positive cells, "3" indicates the higher, but not maximal density of positive cells, and "4" indicates the highest density of positive cells.

2.6. TUNEL Study {#sec2.6}
----------------

The paraffin-embedded sections were also detected for apoptotic cells by TUNEL method. The procedures were according to instruction of the kit (ISCDD, Boehringer Mannheim, Germany) and our laboratory methods \[[@B7]\]. Ten villi and crypts of each section were observed under a light microscope, and the average number of TUNEL-positive cells in 100 counted cells was assigned as the apoptotic index. The distinctive morphological features of apoptosis were used to recognize apoptotic cells. Small clusters of dead cell fragments were assessed as originating from one cell and given a single count, and any doubtful cells were disregarded.

2.7. Statistical Analysis {#sec2.7}
-------------------------

Software SPSS 13.0 was used for the statistical analysis. All data were expressed as mean ± SEM. The measurements were subjected to one-way ANOVA. Differences between experimental groups were determined by Fisher\'s LSD posttest. Significance was assigned at *P* \< .05.

3. Results {#sec3}
==========

3.1. EMSA for NF-*κ*B {#sec3.1}
---------------------

As shown in [Figure 1](#fig1){ref-type="fig"}, low intestinal NF-*κ*B binding activity (weak EMSA autoradiography) was detected in the sham + vehicle group. Compared with sham + vehicle group, NF-*κ*B binding activity in the intestinal tissue was significantly increased in TBI + vehicle group. In TBI + tBHQ group, the intestinal Nrf2 binding activity was significantly downregulated after TBI. The results showed that tBHQ treatment could markedly suppress the activation of NF-*κ*B in the gut following TBI.

3.2. ELISA for Inflammatory Cytokines {#sec3.2}
-------------------------------------

Concentrations of inflammatory cytokines including TNF-*α*, IL-1*β*, and IL-6 were low in the mice gut of sham + vehicle group, as shown in [Figure 2](#fig2){ref-type="fig"}. Compared with sham + vehicle group, intestinal levels of TNF-*α*, IL-1*β*, and IL-6 were greatly induced in TBI + vehicle group. tBHQ administration after TBI could lead to significantly decreased TNF-*α*, IL-1*β*, and IL-6 concentrations in mice intestinal tissue.

3.3. Immunohistochemistry for ICAM-1 {#sec3.3}
------------------------------------

The immunohistochemical assay showed low ICAM-1 immunoreactivity in the villous interstitium and lamina propria in sham + vehicle group; see [Figure 3](#fig3){ref-type="fig"}. Compared to the sham + vehicle group, ICAM-1 in the intestinal tissue was significantly upregulated in TBI + vehicle group. In TBI + tBHQ group, the level of ICAM-1 immunoreactivity was significantly decreased. The results suggested that tBHQ administration could significantly down-regulate the ICAM-1 expression in mice gut following TBI.

3.4. TUNEL for Intestinal Mucosal Apoptosis {#sec3.4}
-------------------------------------------

Low apoptotic index was found in the sham + vehicle group mice intestinal tissue, as shown in [Figure 4](#fig4){ref-type="fig"}. In TBI + vehicle group, the apoptotic index in the studied mice gut was found to be significantly increased compared with that in sham + vehicle group animals. In TBI + tBHQ group, the apoptotic index in the intestinal tissue was significantly decreased. The results suggested that tBHQ treatment could inhibit apoptotic cell death in the intestine and could potentially reduce the mucosal injury following TBI.

4. Discussion {#sec4}
=============

This study revealed that the inflammatory-related factors including NF-*κ*B, proinflammatory cytokines, and ICAM-1 in the intestine were significantly upregulated following TBI and could be suppressed when treated with tBHQ. At the same time, treatment with tBHQ markedly reduced TBI-induced apoptotic cell death in the intestine. These findings reported here suggest for the first time that tBHQ administration can suppress the intestinal inflammation and reduce the mucosal injury following TBI.

To defend against exogenous toxins and injury, cells possess a large number of cytoprotective and detoxifying enzymes whose expression is rapidly increased in response to insults. Many of these genes contain a common promoter element called the antioxidant response element (ARE). Several transcription factors can bind to ARE; however, Nrf2 is the major one that binds to and activates the expression of these ARE-mediated gene products \[[@B19]--[@B21]\]. In recent researches, the central role of Nrf2 in cell survival has been well eatablished in vitro and in vivo \[[@B22], [@B23]\]. Importantly, numerous lines evidence generated in the recent years have implied the anti-inflammatory effect of Nrf2 in a variety of experimental models \[[@B24]--[@B27]\]. Our previous studies showed that in response to TBI, mice lacking Nrf2 exhibited increased intestinal inflammatory response and mucosal injury \[[@B6], [@B7]\]. These provide the evidence that Nrf2 plays an important role in the gut injury after TBI. Upregulation of Nrf2 may bring great benefit to the TBI-induced intestinal inflammatory damage.

Synthetic phenolic antioxidant tBHQ used widely as a food-additive antioxidant for humans has long been of interest as effective inducer of Nrf2 \[[@B14], [@B28], [@B29]\]. There is abundant evidence that tBHQ treatment increases Nrf2 activation and confers protection \[[@B14], [@B30]\]. In vitro studies have shown that, as a result of its action on Nrf2, tBHQ is effective in inducing ARE-dependent gene expression in cultured astrogytes and protecting neurons from oxidative injury \[[@B31]\]. Other in vivo studies have shown that the neuroprotective effect of tBHQ on oxidative stress and ischemic injury is lost in Nrf2-deficient mice \[[@B14], [@B15]\]. Additionally, the majority of tBHQ-induced genes in glia and neurons have been shown to be dependent on Nrf2 by microarray analyses \[[@B29]\]. In light of the findings described above, we hypothesize that activation of Nrf2 with tBHQ may represent an attractive target for combating TBI-induced intestinal inflammatory response and mucosal injury.

The intestinal inflammatory response following trauma is characterized by intestinal recruitments of neutrophils and monocytes through activation of NF-*κ*B, releasing many inflammatory cytokines, and upregulation of adhesion molecule, which has been implicated in the pathogenesis of TBI-induced gastrointestinal dysfunction \[[@B4]\]. NF-*κ*B is one of the most important proinflammatory modulators, which can be activated by lesion-induced oxidative stress, bacterial endotoxin, or cytokines and subsequently transactivate the expression of many cytokines and adhesion molecules \[[@B32]\]. Proinflammatory cytokines, including interleukins (ILs) and TNF-*α* released early after an inflammatory stimulus, can initiate the infiltration of inflammatory cells into the intestine by activating ICAM-1 and other adhesion molecules \[[@B33]\]. NF-*κ*B activation enhances the transcription of proinflammatory cytokines, and the cytokines are known to in turn activate NF-*κ*B \[[@B34]\]. The positive feedback is believed to serve to amplify inflammatory signals and exacerbate tissue injury. Our study showed that at 24 h after TBI, upregulation of NF-*κ*B, TNF-*α*, IL-1*β*, and IL-6 was evident in the intestine and could be inhibited when treated with tBHQ. These results illustrated that tBHQ administration could suppress the intestinal inflammation following TBI.

The major changes of gastrointestinal function after TBI can be summarized into four aspects: gastrointestinal mucosa ischemia, gut motility dysfunction, disruption of gut barrier, and alteration of intestinal mucosal absorptive function. Apoptosis is an important factor in gastrointestinal physiological cell renewal, which can be triggered by noxious stimuli such as trauma and ischemia \[[@B35], [@B36]\]. Previous studies of our laboratory definitely demonstrated that marked apoptosis of the intestinal epithelial cells occurred after TBI, and it was supposed to play an important role in the gut barrier damage and increased permeability of the intestinal epithelium, leading to possible translocation of intraluminal microbes and bacterial toxins \[[@B5], [@B6]\]. However, there is still no effective treatment for the gut mucosa injury caused by TBI. In the present study, we found that at 24 h after TBI, increased intestinal mucosal apoptosis was evident and could be suppressed by tBHQ administration. These results suggested that tBHQ could afford protection to the TBI-induced gut mucosal damage.

Although the precise mechanism regarding the anti-inflammatory ability of tBHQ remains elusive, several lines of evidence indicate that Nrf2 and NF-*κ*B signaling pathways contribute to the pathophysiological process. The prevailing theory is that Nrf2 interferes with inflammatory signaling pathways by inhibiting NF-*κ*B activation through the maintenance of cellular redox status. Oxidative stress from reactive oxygen species (ROS) is believed to be involved in the progression of gastrointestinal dysfunction secondary to TBI \[[@B37]\]. Activation of the NF-*κ*B signaling pathway has been shown to be responsive to excess ROS and is important in the generation of inflammation \[[@B26]\]. The antioxidant transcription factor Nrf2 has been shown to play an important role in limiting ROS levels and thereby affect redox-sensitive NF-*κ*B signaling pathway involved in the inflammation \[[@B19], [@B38]\]. It is therefore implied that tBHQ may play an important role in anti-inflammation by a mechanism of the augmentation of cellular antioxidative system via upregulation of Nrf2 signaling pathway resulting in decreased pro-inflammatory cytokines production and adhesion molecules expression via inactivation of NF-*κ*B signaling pathway. It is assured that further ingenious researches are needed and will be conducted in our laboratory.

In summary, the results showed that oral treatment with tBHQ prior to TBI markedly decreased NF-*κ*B activation, inflammatory cytokines production, and ICAM-1 expression in the gut. Additionally, tBHQ administration significantly attenuated TBI-induced intestinal mucosal apoptosis. These results suggest that tBHQ maybe an effective therapeutic drug for the treatment of TBI-induced gut injury with a potential mechanism of upregulation of Nrf2 signaling pathway.

This work was supported by grants from Drum Tower Hospital of China. The authors thank Dr. Li-zhi Xu and Dr. Geng-bao Feng for their technical assistance. W. Jin, H. Ni, and Y. Dai have contributed equally to this work.

![NF-*κ*B binding activity in the intestinal tissue in sham + vehicle group, TBI + vehicle group, and TBI + tBHQ group (*n* = 6). EMSA autoradiography of NF-*κ*B DNA binding is shown on top of the graph, and the order of individual bands corresponds to that of graph bars. Lane 1: sham + vehicle group; lane 2: TBI + vehicle group; lane 3: TBI + tBHQ group. tBHQ treatment markedly suppressed the activation of NF-*κ*B in the gut following TBI. \*\**P* \< .01 versus sham + vehicle group; ^\#\#^ *P* \< .01 versus TBI + vehicle group.](MI2010-502564.001){#fig1}

![Concentrations of inflammatory cytokines in the intestinal tissue in sham + vehicle group, TBI + vehicle group, and TBI + tBHQ group (*n* = 6). The figure indicates that concentrations of TNF-*α*, IL-1*β*, and IL-6 in the intestine were significantly increased after TBI and could be suppressed when treated with tBHQ. \*\**P* \< .01 versus sham + vehicle group. ^\#^ *P* \< .05 and ^\#\#^ *P* \< .01 versus TBI + vehicle group.](MI2010-502564.002){#fig2}

![Expression of ICAM-1 in the intestinal tissue in sham + vehicle group, TBI + vehicle group, and TBI + tBHQ group (*n* = 6). (a) Sham + vehicle group mice showing low ICAM-1 immunoreactivity. (b) TBI + vehicle group showing increased ICAM-1 immunoreactivity. (c) TBI + tBHQ group mice showing less ICAM-1 immunoreactivity than those of TBI + vehicle group. (d) tBHQ administration significantly downregulated the ICAM-1 expression in mice gut following TBI. \*\**P* \< .01 versus sham + vehicle group; ^\#\#^ *P* \< .01 versus TBI + vehicle group.](MI2010-502564.003){#fig3}

![TUNEL immunohistochemistry staining in the intestinal tissue in sham + vehicle group, TBI + vehicle group, and TBI + tBHQ group (*n* = 6). (a) sham + vehicle group mice showing few TUNEL positive cells (stained brown); (b) TBI + vehicle group mice showing more TUNEL positive cells; (c) TBI + tBHQ group mice showing less TUNEL positive cells than TBI + vehicle group; (d) tBHQ treatment significantly decreased the apoptotic index in the intestinal tissue following TBI. \*\**P* \< .01 versus sham + vehicle group; ^\#\#^ *P* \< .01 versus TBI + vehicle group.](MI2010-502564.004){#fig4}
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